GlassScriptPhysician profile
Julianne Tobin
NPI 1962948489
$3,820.81
in general payments reported to CMS, 2019-2025
28 companies · $74.29 in 2025
The $74.29 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $846 · 2023: $1,178 · 2024: $948 · 2025: $74.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.87 | 2021-2024 | |
| Novo Nordisk INC | $499.24 | 2021-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $434.23 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $343.50 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $270.52 | 2021-2024 | |
| Amgen INC. | $227.88 | 2021-2024 | Prolia, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $196.97 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.25 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $149.33 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $146.97 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $94.20 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Daiichi Sankyo INC. | $82.53 | 2021-2023 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $59.60 | 2021-2023 | Austedo Xr |
| Inspire Medical Systems, INC. | $51.81 | 2024 | Inspire |
| Sanofi Pasteur INC. | $51.20 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $38.92 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $31.89 | 2023-2024 | Voquezna |
| Seqirus USA INC | $28.23 | 2022-2024 | Flucelvax, Fluad |
| Astellas Pharma US INC | $26.23 | 2024 | Veozah |
| Alnylam Pharmaceuticals INC. | $25.74 | 2025 | Onpattro |
| Genentech USA, INC. | $25.20 | 2021 | |
| Abbott Laboratories | $20.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.33 | 2024 | Spravato |
| Alexion Pharmaceuticals, INC. | $16.28 | 2023 | Strensiq |
| Amarin Pharma, INC. | $13.78 | 2021 | |
| Dynavax Technologies Corporation | $13.04 | 2023 | Heplisav-B |
| Esperion Therapeutics, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julianne Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.